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Abstract
Background: Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes high fever, rash, and
recurrent arthritis in humans. It has efficiently adapted to Aedes albopictus, which also inhabits temperate regions
and currently causes large outbreaks in the Caribbean and Latin America. Ebola virus (EBOV) is a member of the
filovirus family. It causes the Ebola virus disease (EDV), formerly known as Ebola hemorrhagic fever in humans and
has a mortality rate of up to 70 %. The last outbreak in Western Africa was the largest in history and has caused
approximately 25,000 cases and 10,000 deaths. For both viral infections no specific treatment or licensed vaccine is
currently available. The bis-hexasulfonated naphthylurea, suramin, is used as a treatment for trypanosome-caused
African river blindness. As a competitive inhibitor of heparin, suramin has been described to have anti-viral activity.
Methods: We tested the activity of suramin during CHIKV or Ebola virus infection, using CHIKV and Ebola envelope
glycoprotein pseudotyped lentiviral vectors and wild-type CHIKV and Ebola virus.
Results: Suramin efficiently inhibited CHIKV and Ebola envelope-mediated gene transfer while vesicular stomatitis virus
G protein pseudotyped vectors were only marginally affected. In addition, suramin was able to inhibit wild-type CHIKV
and Ebola virus replication in vitro. Inhibition occurred at early time points during CHIKV infection.
Conclusion: Suramin, also known as Germanin or Bayer-205, is a market-authorized drug, however shows significant
side effects, which probably prevents its use as a CHIKV drug, but due to the high lethality of Ebola virus infections,
suramin might be valuable against Ebola infections.
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Background
The Chikungunya virus (CHIKV) is a mosquito-
transmitted alphavirus that causes flu-like symptoms
and arthritis. In about 30 % of cases arthritis can last for
months or even years, which may cause substantial
economic losses [1, 2]. The virus currently spreads from
Africa and the Indian Ocean to the Caribbean and Latin
America and is now responsible for large, still-ongoing
outbreaks with 1.7 million suspected cases as of October
2014 (www.cdc.gov). The mortality rate is very low
(0.1 %), but the infection rates are high (about 30 %) and
asymptomatic cases are rare (about 15 %) [3]. Due to
climate change, globalization, and vector switching, the
virus will most likely continue to cause new, worldwide
outbreaks also in more temperate regions like Europe or
the USA [4, 5].
In contrast, Ebola virus (EBOV) belongs to the
filovirus family and is a single (–)-stranded RNA envel-
oped virus. EBOV infections cause Ebola hemorrhagic
fever in humans with mortality rates of up to 70 %. The
last outbreak of EBOV in Western Africa was by far the
largest outbreak in history. As of May 12th, 2016 an esti-
mated number of 28,616 cases and 11.310 deaths have
been reported (www.CDC.gov). For both viral infections
no treatment or licensed vaccine exists [2, 6, 7].
CHIKV, like other alphaviruses, enters cells by
receptor-mediated endocytosis and a subsequent pH-
dependent fusion step. CHIKV has two surface proteins
that mediate cell entry: the transmembrane glycoproteins
E2 and E1. E2 mediates cell attachment and E1 is a class
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II viral fusion protein [8]. EBOV cell entry is mediated by
a single envelope GP that contains the receptor-binding
domain and additionally acts as a fusion protein [9, 10].
Filoviruses utilize a combination of attachment and recep-
tor molecules to enter cells, resulting in a very broad host
range. Many factors have been described to interact with
EBOV, including proteoglycans. After cell binding, EBOV
is taken up by macropinocytosis, followed by low pH-
dependent cathepsin B/L-mediated proteolytic cleavage of
GP. Finally, binding of the GP to the Niemann-Pick C1
(NPC1) protein as an intracellular receptor is re-
quired for the fusion process and virus entry into
the cytoplasm [9, 10].
The early steps of viral infections are carried out by
the viral glycoproteins which mediate attachment and
entry of the virus into the target cell. A tool to investi-
gate the glycoproteins of viruses is the pseudotyping of
lentiviral vectors with the desired glycoproteins (here:
CHIKV or EBOV) [11]. With this strategy, the lentiviral
vectors incorporate a heterologous viral glycoprotein
(GP) and thereby acquire the host range of the virus
from which the glycoprotein is derived. These pseudo-
typed vectors enable studies to be carried out without
the need for using the native virus, which for Ebola virus
reduces the required safety level from the highest level 4
to level 2. We have previously established a chikungunya
virus (CHIKV) neutralization assay in a 384-well format
[12] and adjusted this multiplex assay for Ebola virus,
allowing the analysis of inhibitors of infection in a short
period of time, which in cases of virus outbreaks could
be of decisive advantage.
Proteoglycans are widely distributed molecules on the
cell surface, consisting of a transmembrane protein
linked to sulfated glycosaminoglycans (GAGs). There-
fore, many pathogens exploit GAGs to cross the cell
membrane barrier, using them for initial cell attachment
or as entry receptors. These pathogens include several
bacteria, parasites, and viruses [13, 14]. It has been
shown previously that although CHIKV and Ebola virus
enter cells by different pathways, they both use GAGs
for their attachment to target cells. Soluble GAGs are
able to inhibit pseudotyped vector entry [15–17]. As a
competitive inhibitor of GAGs and heparin, suramin has
been shown to have anti-viral activity. Suramin, also
known as Germanin or Bayer-205, is a market-authorized
drug for the treatment of trypanosome-caused river blind-
ness. It has a negative charge and binds to basic side
chains of proteins. Several viruses have been described to
be inhibited by suramin among them HIV [18, 19] HSV-1
[20], HBV [21], HCV [22], dengue virus [23], EV71 [24],
Rift Valley Fever Virus [25] and recently also CHIKV [26,
27]. Here, we extended these observations for CHIKV and
EBOV by using pseudotyped-lentiviral vectors carrying
envelope glycoproteins and using the wild-type viruses.
Methods
Cell culture
All cells used in this study were cultured at 37 °C under
5 % CO2. HEK 293 T (CRL-1573), MCF7, and Huh7
(CCL-185) cells were grown in Dulbecco’s modified
Eagle medium (DMEM; Lonza, Verviers, Belgium). All
media were supplemented with 10 % FCS (v/v; PAA,
Pasching, Austria), penicillin (50 units/mL), strepto-
mycin (50 μg/mL), and 5 % L-glutamine (200 mM;
Lonza, Verviers, Belgium). Suramin was purchased by
Sigma-Aldrich (Munich, German) with a purity ≥99 %.
Plasmids and DNA
The gene for the CHIKV E3-E1 envelope polyprotein
was expressed from plasmid pIRES2-eGFP-CHIKV
E3-E1 [12] and the Zaire Ebola virus envelope polypro-
tein (pEBOV-GP) gene was obtained from C. Goffinet
[28]. Furthermore, the plasmids pMDLg/pRRE, pRSVrev,
pRRLsinCMV-GFPpre [29], pCSII-Luc [30] (kind gift of
N. Somia) and pHIT-G (encoding VSV-G; [31]) were
used for the production of vector particles.
Lentiviral vector particle production
HEK 293 T cells were seeded in 10 cm dishes in 10 ml
DMEM. After 16 h, subconfluent cells (~80 % density)
were cotransfected with the plasmids pRRLsinCMV-
GFPpre or pCSII-Luc (10 μg), pMDLg/pRRE (6.5 μg),
pRSVrev (2.5 μg), and pHIT-G, pEBOV-GP (3.5 μg) or
pIRES2-eGFP-CHIKV E3-E1 (5.3 μg) using Lipofecta-
mine 2000 (according to the manufacturer’s protocol;
Life Technologies). After 24 h of incubation, the medium
was replaced with 5 ml fresh DMEM per dish. Another
24 h later, the supernatant containing vector particles
was harvested, sterile filtered with 0.45 μm filters
(Sartorius, Göttingen, Germany) and frozen at –80 °C.
Transduction of cells with lentiviral vector particles
All transduction experiments were performed using
DMEM with 1 % FCS. Transduction of cells with
luciferase-encoding lentiviral vectors for luciferase assays
was performed by seeding 6000 HEK 293 T cells per well
in white CELLSTAR 384-well microtiter plates (Greiner
Bio-One, Frickenhausen, Germany) in a volume of 20 μl
DMEM using a MultiFlo Microplate Dispenser (BioTek,
Bad Friedrichshall, Germany) [12] and incubating for
24 h at 37 °C. Suramin (Sigma, Darmstadt) or rabbit sera
(IBT Bioservices, Gaithersburg, MD, USA), were serially
diluted with DMEM until the concentrations were twice
those required for the experiment, mixed 1:1 with vector
particles (either VSV-G, EBOV GP or CHIKV pseudo-
typed, produced with pCSII-Luc), and incubated in
96-U-well plates (Thermo Scientific, Rockford, IL,
USA) at 4 °C for 1 h. The vector particle mixtures
were subsequently added to the cells in the 384-well
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plates using a Matrix Equalizer Multichannel Electronic
Pipette (Thermo Scientific). From every dilution/well in
the 96-well plates, 20 μl were transferred to three wells
each of the 384-well plates (1:2 dilution; triplicate
assay). After 16 h incubation, 20 μl BriteLite substrate
(PerkinElmer, Rodgau, Germany) were added to each
well using the MultiFlo Microplate Dispenser (BioTek).
Following an incubation of 5 min at room temperature,
the luciferase signal was detected with a PHERAstar
FS microplate reader (BMG LABTECH, Ortenberg,
Germany).
Cytotoxicity assay
For the cytotoxicity test, 4 × 104 293 T cells per well in a
96-well plate were seeded and incubated with suramin at
the same concentrations used in the neutralization
assays. Puromycin (2 mg/ml) was used as a positive con-
trol for cell killing, while DMEM in the concentration
used during the neutralization assay served as a negative
control. After incubation for 48 h, the MTT assay was
carried out according to the manufacturer’s instructions
(Merck Millipore, Darmstadt).
Zaire Ebola virus infections
The Mayinga strain of Zaire Ebola virus (EBOV)
(GenBank accession number AF 086833) was used for
infections. The virus was propagated in VeroE6 cells
and titrated by 50 % tissue culture infectious dose
(TCID50) assays. EBOV was preincubated at a multi-
plicity of infection of 0.1 with different concentrations
of suramin (4.6875–300 μg/ml in DMEM containing
no FCS) at 37 °C for 30 min. Huh7 cells were then
infected with ZEBOV and suramin for 1 h at 37 °C.
The inoculum was discarded and the cells were sup-
plied with DMEM (5 % FCS, penicillin, streptomycin)
containing different concentration of suramin. Supernatants
of cells were collected 48 h post infection and their virus
titers were determined by TCID50 analysis. All work with
wild-type EBOV was performed in the biosafety level 4
(BSL4) facility of Philipps University, Marburg.
TCID50 analysis of Ebola virus
VeroE6 cells were cultured in 96-well plates to 50 %
confluence and infected with 10-fold serial dilutions of
supernatants from infected cells (4 replicates). At 7 days
post infection (p.i.), when the cytopathic effect had stabi-
lized, cells were analyzed by light microscopy. The
TCID50/ml was calculated using the Spearman-Kärber
method [32].
CHIKV and VSV infection
The recombinant CHIKV-luci contains the luciferase
gene within the CHIKV nsP3 (non-structural protein 3)
[33]. The virus was generated by in vitro-transcription of
the plasmid pCHIKV-luci after NotI linearization, as de-
scribed previously [34], followed by transfection of the
RNA into BHK-21 cells using Lipofectamine® 2000 (Life
Technologies). Supernatants containing virus were
harvested 48 h later and the virus was amplified on
BHK-21 cells. This replicating luciferase-tagged CHIKV
was used to infect 293 T cells at a low MOI of 0.06 and
viral replication could be simply detected via luciferase
assays. Analogously, VSV infection of target cells was
assessed with a VSV encoding luciferase also at a low
MOI of 0.2 [35].
Statistical data analysis
Mean values and standard deviation (SD) were analyzed
using Microsoft Excel. Half maximal inhibitory concen-
tration (IC50) was calculated using Prism (GraphPad
Software).
Results
Analysis of suramin’s toxicity
Although both viruses enter cells by different pathways,
CHIKV by receptor-mediated endocytosis and a pH-
dependent fusion step and EBOV by a combination of
attachment and receptor molecules in the endosomes,
both viruses attach to cells via GAGs. Consequently
suramin, a competitive inhibitor of GAGs should have
anti-viral activity. To exclude that the inhibitory effect
of suramin is due to toxicity of the compound, the
cytotoxicity of suramin was analyzed by incubating
different cell lines with suramin for 16 h and
performing a MTT assay (Fig. 1). Suramin displayed
only negligible toxicity towards MCF7 however affected
Huh7 and 293 T cell viability starting at a concentration of
50 μg/ml (Fig. 1). The CC50 values were 211 μg/ml for
293 T cells and 182 μg/ml for Huh7 cells. CC50 values for
MCF7 cells were indeterminable. Therefore effects of
Fig. 1 Cytotoxicity of suramin treatment. Cytotoxicity of suramin was
analyzed by incubation of MCF7, Huh7 and 293 T cells with suramin for
16 h and conducting a MTT assay by following the manufacturer’s
instructions (Merck Millipore, Darmstadt). The graph indicates the amount
of viable cells as % of the untreated control and values represent the
mean data of two independent experiments done in duplicate
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suramin at higher concentrations might result from gen-
eral cell toxicity.
Suramin inhibits CHIKV and EBOV pseudotyped vector
transductions
CHIKV and EBOV cell entry are GAG-dependent
[15, 16]. The market-authorized drug suramin has
been described as a competitive inhibitor of GAGs
[36, 37] and thus was tested for its inhibitory activity
towards CHIKV and EBOV-pseudotyped vectors.
Consequently, transduction of 293 T target cells was
performed in the presence of increasing amounts of
suramin. VSV-G pseudotyped lentiviral vectors were
used as a control to exclude effects on the lentiviral
background of the vector system. Figure 2 shows
that CHIKV (Fig. 2a) and EBOV GP-mediated trans-
duction (Fig. 2b) was effectively inhibited by suramin
with a mean half minimal inhibitory concentration
(IC50) of 4,11 ± 0,74 μg/ml for CHIKV and 8,47 ±
3,21 μg/ml for EBOV. VSV-G-mediated gene transfer
was less affected by the presence of suramin (IC50
27,37 ± 11,82) and only high suramin concentrations
diminished VSV-G mediated transduction (Fig. 2a, b).
This implies that suramin is not toxic at the inhibitory
concentrations and only partially inhibits VSV-G-mediated
entry, but is able to specifically and fully block CHIKV and
EBOV GP-mediated entry.
Suramin blocks CHIKV infection at early time points
The inhibitory effect of suramin on CHIKV-pseudotyped
vector particles was confirmed with wild-type CHIKV.
HEK 293 T cells were infected with a replicating
luciferase-tagged CHIKV (CHIKV-luci) in the presence
of suramin. The recombinant CHIKV-luci contains the
luciferase gene within the CHIKV nsP3 (non-structural
protein 3) gene [33] and viral replication can be detected
via luciferase assays. Figure 3a shows a representative
assay with the average values of the experiment done in
triplicates. Here, 293 T cells were infected for 6 h with
CHIKV-luci in the presence of suramin. Increasing doses
of suramin drastically inhibited CHIKV infection of cells
(IC50 7,38 μg/ml) (Fig. 3). Effects on VSV infection of
target cells were assessed with a VSV encoding luciferase
[35]. VSV infection of 293 T cells was only inhibited at
high suramin concentrations (Fig. 3).
To further analyze the mechanism of viral inhibition
by suramin, the drug (10 μg/ml) was added every 30 min
for 2.5 h during infection with CHIKV-luci at a low
MOI of 0.06 and VSV-luci at a MOI of 0.2 and infection
was analyzed after 6 h. Adding the compounds during
(0 h) or 30 min after the infection significantly inhibited
infection compared to the untreated control. Later
addition of the compound had only slight inhibitory
effects, however reduced the infectivity to 80 % of the
untreated control (Fig. 4a). The same kinetic was also
observed when a CHIKV-neutralizing serum was added
at the same time points of infection. These data imply
that suramin acts on viral entry; however, the influence
a
b
Fig. 2 Neutralization assay with suramin. Suramin dissolved in water was
serially diluted, incubated with EBOV GP or VSV-G pseudotyped vector
particles (a) or CHIKV and VSV-G pseudotyped vector particles (b) and
the mixtures were used for transduction of HEK 293 T cells. Neutralizing
activity was determined by detection of relative luciferase units (RLUs).
The data represent a typical assay with the mean values of triplicates
Fig. 3 Suramin inhibits CHIKV infection. Suramin was serially diluted,
incubated with CHIKV-luci or VSV-luci for 30 min and added to 293 T
cells. Its neutralizing activity was detected after 6 h of incubation
as relative luciferase activities. The luciferase activity is shown as
a percentage, relative to the untreated control. The data show a
representative experiment carried out in triplicate
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on later stages of the viral infection cycle might be
caused by inhibition of entry of virus released from
initially infected cells. In contrast, VSV-luci infection
was only inhibited by the neutralizing antibody when
added up to 30 min after infection (Fig. 4b). Suramin
had only a slight inhibitory effect on VSV when added at
all time points of infection.
Suramin blocks EBOV replication
To ascertain the relevance of the data obtained with
EBOV GP pseudotyped lentiviral vectors, suramin was
added in increasing amounts during a wild-type EBOV
infection. The virus, at a multiplicity of infection of 0.1,
was preincubated with suramin for 30 min. The mixture
was then added to Huh7 target cells, washed off after
1 h, and replaced with medium supplemented with sura-
min at the previous concentration. Incubation was con-
tinued for another 48 h. Subsequently, the viral titer was
determined as 50 % tissue culture infectious dose
(TCID50) values on Vero cells (Fig. 5). Corresponding to
the data obtained with EBOV-pseudotyped vectors, there
was a distinct inhibition of EBOV replication by suramin
with an IC50 of 12,58 ± 5,03 μg/ml: even at a low dose,
Ebola virus replication was clearly reduced by up to
1-log. These data confirm that suramin is an inhibitor of
EBOV with a selectivity index of 14,46.
Discussion
Suramin has been used as an antihelmintic for the treat-
ment of onchocerciasis (African river blindness) since
1920, and is still the only treatment against the adult
worms. Suramin is also used with pentamidine to treat
early stages of sleeping sickness (African trypanosomiasis)
[38]. However, the mode of action against the parasites is
still unknown [39]. Suramin is a market-authorized drug
and clinical pharmacology data are available. It is metabol-
ically stable, has a long plasma half-life of 30–60 days in
humans, is poorly absorbed from the gastrointestinal tract
and 80 % of the drug is excreted renally [39, 40].
For the treatment of onchocerciasis, suramin is admin-
istered as a single weekly intravenous injection of 1 g
suramin for 6 weeks, which might be sufficient to obtain
antiviral effects [41]. The most frequent adverse reac-
tions of suramin-treated patients with onchocerciasis
are nausea and vomiting. About 90 % of patients de-
velop a reversible urticarial rash. Kidney damage and
exfoliative dermatitis occur less commonly. Suramin
is also associated with hepatic and bone marrow tox-
icity, Stephens-Johnson syndrome, and death. There is
a greater than 50 % chance of damage to the adrenal
cortex [41]. Other toxic effects of suramin in humans
have been documented during clinical trials in cancer
patients. Reversible liver toxicity, corneal damage, and
adrenal insufficiency have been described frequently
[42]. The LD50 of suramin in mice is 750 mg/kg [43]
after intraperitoneal application and 620 mg/kg fol-
lowing intravenous application [44]. The lowest toxic
dose (TDLo) in humans is 46 mg/kg/5 week on an
intermittent schedule [45].
Since suramin acts as a competitor of heparin, anticoa-
gulating activity might be expected. However, despite
extensive use of suramin, coagulopathy has not been de-
scribed as a side effect of the treatment. Coagulopathy
has only been reported in three female patients receiving
suramin as treatment for metastatic adrenocortical
carcinoma [46]. For this treatment, a higher suramin
dosage of 1.4 g/m2/week was used. The study showed
that suramin itself did not prolong the clotting time, but
a b
Fig. 4 Suramin acts on early steps of CHIKV infections in vitro. HEK 293 T cells were incubated with CHIKV-luci (a) or VSV-luci (b) and suramin
(10 μg/ml). The drug was added during the infection (0 h) and then every 30 min after infection up to 2.5 h after infection. After 6 h, infected
cells were detected as relative luciferase activities. CHIKV infection without treatment was set to 100 %
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rather a suramin-related anticoagulant, which was het-
erogeneous in the three patients [46].
Here we have shown that suramin’s toxicity is cell line
dependent and highest in HEK 293 T and Huh7 cells,
whereas MCF7 cells were only marginally affected.
Suramin is able to inhibit CHIKV infections. This has
been observed before by others [26, 27]. However the
mode of action is still unclear. Inhibition of pseudotyped
vector transduction and time of drug-addition experi-
ments indicate an effect on viral entry, as observed by
Ho et al. [27]. Nevertheless, except the recurrent
arthritis, CHIKV fever is, compared to Ebola virus infec-
tions, a rather mild disease and the unwanted side ef-
fects of suramin might make it inappropriate for the
treatment of CHIKV infections. On the other hand,
suramin is able to inhibit Ebola virus pseudotyped lenti-
viral vectors as well as wild-type Ebola virus in vitro and
the severity of the disease makes suramin a therapeutic
option as long as more specific drugs are not available.
VSV-G pseudotyped vector entry was only slightly inhib-
ited by suramin, but never declined to undetectable
levels (Fig. 2). This indicates that the inhibition of CHIKV
or EBOV entry by suramin uses a different mechanism to
that of VSV. Suramin might bind directly to the cell at-
tachment site of the GPs, similar like soluble GAGs and
thereby directly compete with cell binding.
Recently, large screens of Food and Drug Administra-
tion (FDA)-approved drugs were performed with EBOV
VLPs and identified 53 drugs that are able to inhibit
EBOV infections [47]. Microtubule inhibitors were the
most potent Ebola virus entry inhibitors, with IC50
values in the low μM range. However, wild-type virus
has not yet been used to confirm the drug activity [47].
Others have reported that amiodarone, a multi-ion
channel inhibitor and adrenoceptor antagonist, is a
potent inhibitor of EBOV cell entry at concentrations
reported to be achievable in plasma in humans [48]. All
drugs described so far have a broad mode of action and
unwanted side effects might be envisioned. Correspond-
ingly, the wide range of toxicities might require im-
proved analogs of suramin. It should, however, be tested
in animal models, which can provide indications about
the feasibility of using suramin for Ebola treatment. The
last EBOV epidemic in Western Africa was the largest in
history with over 10,000 confirmed deaths. Earlier out-
breaks only caused a few hundred cases. The long time
period until the epidemic was under control and the
high case fatality rate (about 41 % for the last outbreak)
make rapid and effective actions an urgent requirement
for future outbreaks. Suramin treatment of EBOV
patients might be option for this, as several decades of
treatment experience with other pathogens, especially in
Africa, are available. Additionally, suramin can be easily
produced in high amounts and would be available im-
mediately. The high lethality of Ebola virus infection
makes mild side effects of the treatment acceptable as
long as there is no better treatment available. Addition-
ally and in parallel, improvements to the drug to reduce
unwanted side effects should be attempted.
Conclusion
Suramin inhibits CHIKV and EBOV infections in vitro.
Suramin might have too many unwanted side effects for
the treatment of CHIKV infections, however might be
acceptable for the treatment of Ebola virus infections as
long as there is no better treatment available. However,
appropriate animal models have to show in vivo applic-
ability first.
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